Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530529 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01530529 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT01530529, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. One dose of the modified-release formulation will also be evaluated in the presence of food.
Interventions
- DRUG PF-05180999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01530529
The ClinicalTrials.gov registry entry for NCT01530529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05180999 is the first listed.
NCT01530529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01530529 about?
NCT01530529 is a clinical study titled "A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999". The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulatio...
What is the current status of trial NCT01530529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01530529?
The interventions under investigation include: PF-05180999 (DRUG).
Who is sponsoring clinical trial NCT01530529?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.